Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Leuk Lymphoma. 2021 Dec;62(13):3308-3310. doi: 10.1080/10428194.2021.1957877. Epub 2021 Jul 26.

Authors

Daniel Re^{1

2}, Jérôme Barrière³, Emmanuel Chamorey⁴, Margaux Delforge⁵, Lauris Gastaud², Emmanuel Petit³, Axel Chaminade³, Benjamin Verrière⁵, Frédéric Peyrade²

Affiliations

¹ Department of Medical Oncology, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.
² Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
³ Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France.
⁴ Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France.
⁵ Department of Pharmacy, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.

PMID: 34308748
DOI: 10.1080/10428194.2021.1957877

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19*
Hematologic Neoplasms* / therapy
Humans
RNA, Messenger
SARS-CoV-2
Seroconversion
Vaccination

Substances

Antibodies, Viral
RNA, Messenger